What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
His primary scientific interests are in Internal medicine, Lymphoma, Oncology, Rituximab and Surgery.
Jonathan W. Friedberg focuses mostly in the field of Internal medicine, narrowing it down to matters related to Gastroenterology and, in some cases, Febrile neutropenia.
He specializes in Lymphoma, namely Follicular lymphoma.
His Follicular lymphoma research includes elements of Prospective cohort study and Chronic lymphocytic leukemia.
His biological study spans a wide range of topics, including International Prognostic Index, Diffuse large B-cell lymphoma, Clinical trial, Survival rate and Leukemia.
His work deals with themes such as Hematology, Tolerability and Radioimmunotherapy, which intersect with Rituximab.
His most cited work include:
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma (1549 citations)
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia (658 citations)
- An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era (435 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Oncology, Lymphoma, Rituximab and Follicular lymphoma.
His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology, Surgery and Immunology.
Jonathan W. Friedberg interconnects CHOP, Clinical trial, Non-Hodgkin's lymphoma and Hodgkin lymphoma in the investigation of issues within Oncology.
Jonathan W. Friedberg works mostly in the field of Lymphoma, limiting it down to topics relating to Cancer research and, in certain cases, Apoptosis and Proteasome inhibitor, as a part of the same area of interest.
His Rituximab study which covers Vincristine that intersects with Prednisone.
His Follicular lymphoma research is multidisciplinary, relying on both Radioimmunotherapy, Prospective cohort study and Hazard ratio.
He most often published in these fields:
- Internal medicine (68.57%)
- Oncology (47.55%)
- Lymphoma (38.37%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (68.57%)
- Oncology (47.55%)
- Lymphoma (38.37%)
In recent papers he was focusing on the following fields of study:
Jonathan W. Friedberg mainly investigates Internal medicine, Oncology, Lymphoma, Rituximab and Hodgkin lymphoma.
His study in Internal medicine concentrates on Brentuximab vedotin, Follicular lymphoma, Chemotherapy, Vincristine and Prednisone.
His Oncology study combines topics in areas such as Classical Hodgkin lymphoma, Diffuse large B-cell lymphoma, Phases of clinical research and Lenalidomide.
His Lymphoma study also includes fields such as
- Clinical trial which connect with Positron emission tomography,
- Refractory most often made with reference to Cancer research.
He has researched Rituximab in several fields, including Randomized controlled trial, Autologous transplantation and Progression-free survival.
The various areas that he examines in his Hodgkin lymphoma study include Chemotherapy regimen, Older patients and Pediatrics.
Between 2017 and 2021, his most popular works were:
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial (182 citations)
- Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303 (85 citations)
- Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. (66 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
His main research concerns Internal medicine, Oncology, Rituximab, Lymphoma and Vincristine.
Internal medicine is often connected to Gastroenterology in his work.
His research in Oncology intersects with topics in Clinical trial, Lenalidomide, EPOCH, Young adult and Hazard ratio.
The Rituximab study combines topics in areas such as Mantle cell lymphoma, Follicular lymphoma, Progression-free survival and Diffuse large B-cell lymphoma.
His work carried out in the field of Lymphoma brings together such families of science as Follicular phase, Cancer research, Phases of clinical research, MEDLINE and Treatment options.
His Vincristine study also includes
- Prednisone that intertwine with fields like Cyclophosphamide,
- International Prognostic Index that intertwine with fields like Gene rearrangement and Peripheral T-cell lymphoma.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
